TrialSignal
Clinical trial intelligence report
Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02719002-Jul 28, 2026
NCT ID
NCT02719002
Status
COMPLETED
Phase
NA
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Executive brief
Investment-Ready Snapshot
Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials is a NA clinical asset sponsored by Fondation Ophtalmologique Adolphe de Rothschild in Toxicity, Drug, Maculopathy. SEO and diligence focus: spectral domain optical coherence tomography C-scan and multifocal electroretinogram, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02719002
Indication
Toxicity, Drug
Modality
medical device
Target
spectral domain optical coherence tomography C-scan and multifocal electroretinogram
Intervention
spectral domain optical coherence tomography C-scan and multifocal electroretinogram
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.